C-192

C-192 is a novel tetra-specific biologic drug developed using the UniStac enzyme-mediated conjugation platform. It is designed to simultaneously target four key molecules implicated in non-alcoholic steatohepatitis (NASH): glucagon-like peptide 1 (GLP-1), glucagon (GCG), fibroblast growth factor 21 (FGF21), and interleukin-1 receptor antagonist (IL-1RA). By integrating these mechanisms, C-192 aims to address the complex pathophysiology of NASH, which involves metabolic dysfunction, chronic inflammation, and liver injury. Preclinical studies demonstrated that C-192 significantly improved markers of liver health—including alanine transaminase levels, triglyceride accumulation, and NAFLD activity score—outperforming conventional drugs such as liraglutide and dulaglutide[1][2]. The drug’s multi-target approach leverages both metabolic regulation and anti-inflammatory effects.